Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Completed · Phase 4

Conditions studied: Relapsing Remitting Multiple Sclerosis

In brief

Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. * To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab. * To evaluate as needed re-treatment with alemtuzumab and other DMTs.

Key facts

Study ID

NCT02255656

Run by

Genzyme, a Sanofi Company

People needed

1062

Starts

2015-01-07

Expected to finish

2020-07-15

Last updated by the study team

2022-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant had completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form.

You may not qualify if…

• Participant participating in another investigational interventional study.
• The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 1031 — Phoenix, Arizona, United States
• Investigational Site Number 1171 — Phoenix, Arizona, United States
• Investigational Site Number 1090 — Tucson, Arizona, United States
• Investigational Site Number 1040 — Berkeley, California, United States
• Investigational Site Number 1152 — Fullerton, California, United States
• Investigational Site Number 1093 — Pasadena, California, United States
• Investigational Site Number 1027 — Fort Collins, Colorado, United States
• Investigational Site Number 1078 — Jacksonville, Florida, United States
• Investigational Site Number 1059 — Maitland, Florida, United States
• Investigational Site Number 1173 — Sarasota, Florida, United States
• Investigational Site Number 1034 — Sunrise, Florida, United States
• Investigational Site Number 1005 — Tampa, Florida, United States
• Investigational Site Number 1049 — Tampa, Florida, United States
• Investigational Site Number 1008 — Northbrook, Illinois, United States
• Investigational Site Number 1001 — Fort Wayne, Indiana, United States
• Investigational Site Number 1024 — Indianapolis, Indiana, United States
• Investigational Site Number 1017 — Des Moines, Iowa, United States
• Investigational Site Number 1022 — Kansas City, Kansas, United States
• Investigational Site Number 1083 — Lenexa, Kansas, United States
• Investigational Site Number 1039 — Lexington, Kentucky, United States
• Investigational Site Number 1021 — Louisville, Kentucky, United States
• Investigational Site Number 1061 — Wellesley, Massachusetts, United States
• Investigational Site Number 1028 — Worcester, Massachusetts, United States
• Investigational Site Number 1025 — Ann Arbor, Michigan, United States
• Investigational Site Number 1086 — Cullman, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.